Milestone Pharmaceuticals Inc. Files 2023 Annual Report on Form 10-K

Ticker: MIST · Form: 10-K · Filed: Mar 21, 2024 · CIK: 1408443

Sentiment: neutral

Topics: 10-K, Milestone Pharmaceuticals, Financial Report, Stock Plans, Pharmaceuticals

TL;DR

<b>Milestone Pharmaceuticals Inc. filed its 2023 10-K, detailing financial data and corporate plans.</b>

AI Summary

Milestone Pharmaceuticals Inc. (MIST) filed a Annual Report (10-K) with the SEC on March 21, 2024. Milestone Pharmaceuticals Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The company's principal executive offices are located at 1111 Boul. Dr.-Frederik-Philips, Ste 420, Montreal, A8, H4M 2X6. The filing includes data related to various stock and warrant plans, including the Restated Share Option Plan 2011 and the Equity Incentive Plan 2019. Subsequent events noted include strategic financing agreements and an over-allotment option exercised on February 28, 2024. The SIC code for Milestone Pharmaceuticals Inc. is 2834 (Pharmaceutical Preparations).

Why It Matters

For investors and stakeholders tracking Milestone Pharmaceuticals Inc., this filing contains several important signals. The 10-K filing provides a comprehensive overview of the company's financial health, operational activities, and strategic initiatives for the fiscal year 2023, which is crucial for investors to assess performance and future prospects. Details on stock and warrant plans, along with subsequent financing events, offer insights into the company's capital structure and its ability to fund future operations and growth.

Risk Assessment

Risk Level: medium — Milestone Pharmaceuticals Inc. shows moderate risk based on this filing. The company operates in the pharmaceutical industry, which is subject to significant regulatory hurdles, lengthy development cycles, and intense competition, posing inherent risks to its financial performance and market position.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Milestone Pharmaceuticals' current financial standing and potential challenges.

Key Numbers

Key Players & Entities

FAQ

When did Milestone Pharmaceuticals Inc. file this 10-K?

Milestone Pharmaceuticals Inc. filed this Annual Report (10-K) with the SEC on March 21, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Milestone Pharmaceuticals Inc. (MIST).

Where can I read the original 10-K filing from Milestone Pharmaceuticals Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Milestone Pharmaceuticals Inc..

What are the key takeaways from Milestone Pharmaceuticals Inc.'s 10-K?

Milestone Pharmaceuticals Inc. filed this 10-K on March 21, 2024. Key takeaways: Milestone Pharmaceuticals Inc. filed its 10-K report for the fiscal year ending December 31, 2023.. The company's principal executive offices are located at 1111 Boul. Dr.-Frederik-Philips, Ste 420, Montreal, A8, H4M 2X6.. The filing includes data related to various stock and warrant plans, including the Restated Share Option Plan 2011 and the Equity Incentive Plan 2019..

Is Milestone Pharmaceuticals Inc. a risky investment based on this filing?

Based on this 10-K, Milestone Pharmaceuticals Inc. presents a moderate-risk profile. The company operates in the pharmaceutical industry, which is subject to significant regulatory hurdles, lengthy development cycles, and intense competition, posing inherent risks to its financial performance and market position.

What should investors do after reading Milestone Pharmaceuticals Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand Milestone Pharmaceuticals' current financial standing and potential challenges. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,508 words · 18 min read · ~15 pages · Grade level 15.7 · Accepted 2024-03-21 07:01:04

Key Financial Figures

Filing Documents

Business

Item 1. Business 7

Risk Factors

Item 1A. Risk Factors 48

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 93

Cybersecurity

Item 1C. Cybersecurity 93

Properties

Item 2. Properties 95

Legal Proceedings

Item 3. Legal Proceedings 95

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 95 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 96

Selected Financial Data

Item 6. Selected Financial Data 96

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 97

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 110

Financial Statements

Item 8. Financial Statements 111

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 135

Controls and Procedures

Item 9A. Controls and Procedures 135

Other Information

Item 9B. Other Information 136

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 136 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 137

Executive Compensation

Item 11. Executive Compensation 137

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 137

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 137

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 137 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 138

Form 10-K Summary

Item 16. Form 10-K Summary 140 2 Table of Contents "Milestone Pharmaceuticals" and the Milestone logo appearing in this Annual Report on Form 10-K are unregistered trademarks of Milestone Pharmaceuticals Inc. All other trademarks, trade names and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Annual Report on Form 10-K may be referred to without the and symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto. This Annual Report on Form 10-K contains references to United States dollars and Canadian dollars. All dollar amounts referenced, unless otherwise indicated, are expressed in United States dollars. References to "$" are to United States dollars and references to "C$" are to Canadian dollars. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "positioned," "potential," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. We have based these forward-looking statements largely on our current expectations

BUSINESS

ITEM 1. BUSINESS Company Overview We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our lead product candidate etripamil is a novel and potent calcium channel blocker that we designed as a rapid-onset nasal spray to be self-administered by patients. We are developing etripamil for the treatment of specific heart arrhythmias with a lead indication to treat paroxysmal supraventricular tachycardia, or PSVT, and a subsequent indication to treat atrial fibrillation with rapid ventricular rate, or AFib-RVR. PSVT is a condition that causes a patient's heart to suddenly start beating faster than normal. It can be life-altering as PSVT is highly symptomatic, characterized by unpredictable attacks of a racing heart, often exceeding 150 beats per minute. Symptoms of PSVT arise suddenly and may include palpitations, sweating, chest pressure or pain, shortness of breath, sudden onset of fatigue, lightheadedness or dizziness, fainting, and anxiety, causing many patients to interrupt their daily activities at the time of symptom-onset. The impact and morbidity from an episode of PSVT can be especially detrimental in patients with underlying cardiovascular or medical conditions, such as heart failure, obstructive coronary disease, or dehydration. The uncertainty of when such an attack of PSVT will strike or how long it will persist is often anxiety-provoking, reduces patients' quality of life and prevents participation in many desired activities. Drugs approved for the treatment of PSVT attacks include adenosine, verapamil, and diltiazem, with all being administered intravenously under medical supervision, usually in the emergency department. Other oral drugs are sometimes used to treat attacks in a concept called "pill in the pocket." However, those drugs have never been proven effective or safe and are not approved for this use. Doctors are frustrated by the lack of effective treatment options besides

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing